A specialist dried blood spot (DBS) or liquid blood sample test measuring maternal DHA status during pregnancy. DHA (docosahexaenoic acid) is critical for foetal brain and retinal development, yet most pregnant women worldwide are deficient.
Docosahexaenoic acid (DHA) is a long-chain omega-3 polyunsaturated fatty acid that plays a fundamental role in human development. During pregnancy, maternal DHA is the sole source of this essential nutrient for the developing foetus, making adequate maternal status critically important.
DHA is the predominant structural fatty acid in the cerebral cortex, accounting for approximately 25% of total brain fatty acids. During the third trimester, the foetal brain undergoes rapid growth and accumulates DHA at an accelerated rate. Insufficient maternal DHA supply during this window can compromise neurodevelopmental outcomes, including cognitive function, attention, and learning capacity in early childhood.
The retina contains the highest concentration of DHA of any tissue in the human body, comprising up to 60% of the polyunsaturated fatty acids in photoreceptor membranes. Adequate maternal DHA status during pregnancy is essential for optimal visual acuity development in the infant.
Multiple randomised controlled trials and meta-analyses have demonstrated that higher maternal DHA status is associated with a reduced risk of early preterm birth (before 34 weeks). The Cochrane Review of omega-3 supplementation in pregnancy found a 42% reduction in the risk of early preterm birth with adequate omega-3 intake.
Despite the well-established importance of DHA, studies consistently show that the majority of pregnant women in Western countries do not meet the recommended intake of 200–300 mg DHA per day, and blood DHA levels in pregnancy are often suboptimal.
The Prenatal DHA test measures DHA as a percentage of total red blood cell fatty acids from a dried blood spot (DBS) or liquid blood sample, providing a focused, clinically actionable assessment of maternal DHA status.
| Biomarker | Clinical Relevance |
|---|---|
| DHA % of total fatty acids | Primary measure of maternal DHA status; directly reflects dietary intake and placental transfer capacity. Pregnancy-tuned reference ranges: Low (<2.2%), Suboptimal (2.2–4.9%), Optimal (4.9–8.0%), Elevated (>8.0%) |
The report includes pregnancy-specific reference ranges, a personalised EPA+DHA dose recommendation, dietary guidance with a meal plan, progress tracking for trimester-by-trimester monitoring, and interpretive commentary for healthcare providers.
The Prenatal DHA test is designed for healthcare professionals and organisations working in maternal and prenatal health.
DHA testing can provide valuable information at multiple stages of the reproductive journey. Timing recommendations include:
Ideally, DHA status should be assessed before conception. Building adequate DHA stores prior to pregnancy ensures optimal supply during the critical early weeks of neural tube and brain development, before many women are aware they are pregnant.
Baseline DHA testing early in pregnancy establishes a starting point for monitoring. If levels are low, supplementation can begin immediately to improve status before the high-demand period of the third trimester.
A mid-pregnancy test can confirm whether supplementation is raising DHA levels effectively or whether dose adjustments are needed. This is particularly important for women with poor dietary omega-3 intake or those following vegetarian or vegan diets.
The third trimester represents the peak period of foetal DHA accumulation. Testing at this stage verifies that maternal stores are sufficient to meet the accelerated demand. Low DHA in the third trimester has been most strongly associated with increased preterm birth risk.
The importance of DHA in pregnancy is supported by a substantial body of peer-reviewed research:
Partner with Fatty Acid Labs for validated, scalable Omega-3 and fatty acid testing. Wholesale pricing, branded kits, and full laboratory support.